Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer
Oncologist - United States
doi 10.1634/theoncologist.2018-0150
Full Text
Open PDFAbstract
Available in full text
Date
September 26, 2018
Authors
Publisher
Alphamed Press